Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease

Biological Agents for Moderately to Severely Active Ulcerative Colitis

(2014) Silvio Danese et al.   ANNALS OF INTERNAL MEDICINE

Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies

(2013) Alexandra D. Frolkis et al.   GASTROENTEROLOGY

Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

Recent developments in the treatment of inflammatory bowel disease

(2013) Svend T. Rietdijk et al.   Journal of Digestive Diseases

Ulcerative colitis

(2012) Ingrid Ordás et al.   LANCET

Crohn's disease

(2012) Daniel C Baumgart et al.   LANCET

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Guidelines for the management of inflammatory bowel disease in adults

(2011) C. Mowat et al.   GUT

Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis

(2011) John Paul Leombruno et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

(2009) William J. Sandborn et al.   GASTROENTEROLOGY

Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up

(2009) Shane M. Devlin et al.   MEDICAL CLINICS OF NORTH AMERICA

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

(2008) E.F. Stange et al.   Journal of Crohns & Colitis

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET